Literature DB >> 24440286

Thymoma-associated myasthenia gravis: On the search for a pathogen signature.

Perrine Cufi1, Patrick Soussan2, Frédérique Truffault1, Rachid Fetouchi2, Marieke Robinet1, Elie Fadel3, Sonia Berrih-Aknin1, Rozen Le Panse4.   

Abstract

Myasthenia gravis (MG) is an autoimmune disease mainly mediated by anti-acetylcholine receptor (AChR) antibodies. In the late onset, a thymoma, tumor of the thymus, is quite frequent. However, the events leading to thymoma and MG are not understood. As thymoma-associated MG (MG-T) patients also display anti-interferon type I (IFN-I) neutralizing antibodies, we investigated if MG-T could be associated with an anti-viral signature. RT-PCR analyses demonstrated huge increases of IFN-I subtypes, IFN-α2, -α8, -ω and -β, in thymoma-associated MG but not in thymomas without MG or in control thymuses. Next, we investigated if dsRNA signaling pathway involvement could be observed in MG-T, as recently observed in early-onset MG. We observed an abnormal regulation of dsRNA-sensing molecules with an increase of toll-like receptor 3 (TLR3), and a decrease of protein kinase R (PKR) and dsRNA helicases (RIG-I and MDA5) in thymoma from MG patients. We also detected a decreased expression of p53, the tumor suppressor that is known to be down-regulated by dsRNA. Altogether, these results strongly suggest that MG-T could be linked to a viral infection. As p16 (CDKN2A), a marker of HPV infections, was up-regulated in MG-T, we thus screened DNA from thymomas for human papillomavirus (HPV) by real-time PCR using HPV consensus SPF10 primers. RT-PCR results were negative for all samples tested. We confirmed the absence of HPV DNA detection by end point PCR using FAP primers to amplify a larger panel of HPV genotypes. Our data clearly demonstrate INF-I overexpression together with the activation of innate immunity pathways in thymoma-associated MG suggesting that MG might develop after a pathogen infection. We were not able to relate thymoma to HPV infections and the implication of other pathogens is discussed.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Innate immunity; Interferon type I; Myasthenia gravis; Thymoma; Toll-like receptors; Virus

Mesh:

Substances:

Year:  2014        PMID: 24440286     DOI: 10.1016/j.jaut.2013.12.018

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  12 in total

1.  The Integrated Genomic Landscape of Thymic Epithelial Tumors.

Authors:  Milan Radovich; Curtis R Pickering; Ina Felau; Gavin Ha; Hailei Zhang; Heejoon Jo; Katherine A Hoadley; Pavana Anur; Jiexin Zhang; Mike McLellan; Reanne Bowlby; Thomas Matthew; Ludmila Danilova; Apurva M Hegde; Jaegil Kim; Mark D M Leiserson; Geetika Sethi; Charles Lu; Michael Ryan; Xiaoping Su; Andrew D Cherniack; Gordon Robertson; Rehan Akbani; Paul Spellman; John N Weinstein; D Neil Hayes; Ben Raphael; Tara Lichtenberg; Kristen Leraas; Jean Claude Zenklusen; Junya Fujimoto; Cristovam Scapulatempo-Neto; Andre L Moreira; David Hwang; James Huang; Mirella Marino; Robert Korst; Giuseppe Giaccone; Yesim Gokmen-Polar; Sunil Badve; Arun Rajan; Philipp Ströbel; Nicolas Girard; Ming S Tsao; Alexander Marx; Anne S Tsao; Patrick J Loehrer
Journal:  Cancer Cell       Date:  2018-02-12       Impact factor: 31.743

Review 2.  Review on Toll-Like Receptor Activation in Myasthenia Gravis: Application to the Development of New Experimental Models.

Authors:  Marieke Robinet; Solène Maillard; Mélanie A Cron; Sonia Berrih-Aknin; Rozen Le Panse
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

Review 3.  Autoimmunity in 2014.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2015-10       Impact factor: 8.667

4.  A Systematic Review of the Potential Implication of Infectious Agents in Myasthenia Gravis.

Authors:  Victoria Leopardi; Yu-Mei Chang; Andrew Pham; Jie Luo; Oliver A Garden
Journal:  Front Neurol       Date:  2021-06-14       Impact factor: 4.003

5.  Systems biology of myasthenia gravis, integration of aberrant lncRNA and mRNA expression changes.

Authors:  ZhaoHui Luo; Ye Li; XiaoFang Liu; MengChuan Luo; LiQun Xu; YueBei Luo; Bo Xiao; Huan Yang
Journal:  BMC Med Genomics       Date:  2015-03-18       Impact factor: 3.063

6.  Blood Transcriptome Profiling in Myasthenia Gravis Patients to Assess Disease Activity: A Pilot RNA-seq Study.

Authors:  Kee Hong Park; Junghee Jung; Jung-Hee Lee; Yoon-Ho Hong
Journal:  Exp Neurobiol       Date:  2016-02-22       Impact factor: 3.261

7.  Epstein-Barr virus in tumor-infiltrating B cells of myasthenia gravis thymoma: an innocent bystander or an autoimmunity mediator?

Authors:  Paola Cavalcante; Stefania Marcuzzo; Sara Franzi; Barbara Galbardi; Lorenzo Maggi; Teresio Motta; Raffaella Ghislandi; Antonella Buzzi; Luisella Spinelli; Lorenzo Novellino; Fulvio Baggi; Carlo Antozzi; Fabio Conforti; Tommaso Martino De Pas; Massimo Barberis; Pia Bernasconi; Renato Mantegazza
Journal:  Oncotarget       Date:  2017-09-08

8.  The Cancer Genome Atlas dataset-based analysis of aberrantly expressed genes by GeneAnalytics in thymoma associated myasthenia gravis: focusing on T cells.

Authors:  Jianying Xi; Liang Wang; Chong Yan; Jie Song; Yang Song; Ji Chen; Yongjun Zhu; Zhiming Chen; Chun Jin; Jianyong Ding; Chongbo Zhao
Journal:  J Thorac Dis       Date:  2019-06       Impact factor: 2.895

9.  Myasthenia gravis as a prognostic marker in patients with thymoma.

Authors:  Bernardo Cacho-Díaz; Karen Salmerón-Moreno; Nydia A Lorenzana-Mendoza; Julia Texcocano; Oscar Arrieta
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

10.  Expression of pRb and p16INK4 in human thymic epithelial tumors in relation to the presence of human polyomavirus 7.

Authors:  Marlies Keijzers; Dorit Rensspiess; Sreedhar Pujari; Myrurgia A Abdul-Hamid; Monique Hochstenbag; Anne-Marie Dingemans; Anna Kordelia Kurz; Anke Haugg; Jos G Maessen; Marc H De Baets; Axel Zur Hausen
Journal:  Diagn Pathol       Date:  2015-11-04       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.